口服普萘洛尔联合595 nm脉冲染料激光治疗高风险婴幼儿血管瘤

Oral propranolol combined with 595 nm pulsed dye laser in the treatment of high risk infantile hemangioma

目的探讨口服普萘洛尔联合595 nm脉冲染料激光治疗高风险婴幼儿血管瘤的临床疗效。方法自2014年8月至2018年8月,对116例高风险婴幼儿血管瘤采取口服普萘洛尔联合595 nm脉冲染料激光治疗,普萘洛尔口服剂量为1 mg/(kg·d),3次/d,持续6~12个月;595 nm脉冲染料激光照射:1次/月。随访12个月观察每月瘤体性状变化及并发症情况;根据瘤体缩小情况及超声检查评价其疗效。结果本组共116例患儿,49例治愈,60例显效,5例好转,2例无效,总有效率98.27%;12例(10.34%)出现食欲减退、腹泻、色素沉着等并发症。结论口服普萘洛尔联合595 nm脉冲染料激光治疗高风险婴幼儿血管瘤安全、有效,不良反应较少。

Objective To explore the clinical efficacy of oral propranolol combined with 595 nm pulsed dye laser in the treatment of high risk infantile hemangioma. Methods From August 2014 to August 2018, 116 cases of high risk infantile hemangiomas were treated by oral propranolol combined with 595 nm pulsed dye laser. The dose of oral propranolol was 1 mg/(kg·d), 3 times/d for 6 to 12 months.The treatment of 595 nm pulsed dye laser was 1 time a month. All patients were followed up for 12 months. The shape, properties and complications of hemangioma were observed every month. The curative effect was evaluated according to the ultrasonic examination and the reduction of tumor size. Results There were 116 patients in this study, 49 patients were cured, 60 patients effective, 5 patients were improved and 2 patients were ineffective. The total effective rate was 98.27%. Complications such as lack of appetite, diarrhea and pigmentation occurred in 12 patients(10.34%). Conclusion The application of oral propranolol combined with 595 nm pulsed dye laser in the treatment of high risk infantile hemangioma is safe and effective. The occurrence of complications is less.